ストックスクリーナーアプリを入手
14.66
0.48%
-0.07
前日終値:
$14.73
開ける：
$14.76
24時間の取引高:
904.41K
Relative Volume:
0.72
時価総額：
$12.24B
収益：
$3.85B
当期純損益:
$667.93M
株価収益率:
22.31
EPS:
0.657
ネットキャッシュフロー:
$142.30M
1週間 パフォーマンス:
+2.23%
1か月 パフォーマンス:
+5.39%
6か月 パフォーマンス:
+17.00%
1年 パフォーマンス:
-8.66%
1日の値動き範囲:
$14.61
$14.76
1週間の範囲:
$14.15
$14.76
52週間の値動き範囲:
$12.26
$16.19
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
RDY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.66 | 12.14B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-12-19 | ダウングレード | Nomura | Buy → Neutral |
| 2024-01-11 | ダウングレード | Jefferies | Buy → Underperform |
| 2023-08-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-05-18 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-30 | 開始されました | JP Morgan | Underweight |
| 2022-11-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | 再開されました | BofA Securities | Neutral |
| 2021-07-27 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-09-18 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-09-18 | アップグレード | Investec | Sell → Hold |
| 2020-01-28 | ダウングレード | CLSA | Buy → Outperform |
| 2020-01-27 | ダウングレード | CLSA | Buy → Outperform |
| 2020-01-09 | アップグレード | Citigroup | Sell → Buy |
| 2019-11-04 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | アップグレード | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | アップグレード | Macquarie | Neutral → Outperform |
| 2019-06-20 | 開始されました | Deutsche Bank | Hold |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-20 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | アップグレード | CLSA | Outperform → Buy |
| 2019-01-17 | ダウングレード | Citigroup | Neutral → Sell |
| 2017-09-21 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | アップグレード | CLSA | Underperform → Outperform |
| 2017-07-28 | ダウングレード | CLSA | Underperform → Sell |
| 2016-07-27 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2016-07-27 | ダウングレード | Jefferies | Hold → Underperform |
| 2016-02-10 | アップグレード | Credit Agricole | Underperform → Buy |
| 2015-11-10 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Dr Reddys Laboratories Ltd Adr (RDY) 最新ニュース
Asian ADRs Gain As Investors Show Renewed Interest - Finimize
Asian Equities In The US Logged Broad Gains This Session - Finimize
Mixed Performance For Asian Stocks Traded In The US - Finimize
Invesco Ltd. Has $8.12 Million Stake in ATRenew Inc. Sponsored ADR $RERE - Defense World
Validea's Top Health Care Stocks Based On Peter Lynch8/25/2025 - Nasdaq
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Barchart.com
National Bank of Canada FI Boosts Stock Position in Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asian ADRs Trade Lower As S&P Asia 50 Index Drops - Finimize
Asian Tech Names Lift US-Traded Stocks To A Small Gain - Finimize
LLY Stock Quote Price and Forecast - CNN
Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval - TipRanks
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India - MSN
Asian Stocks In The US See Mixed Moves Across Sectors - Finimize
Trump hikes tariffs on India by additional 25% citing Russian oil trade; iShares India ETF, ADRs react - Moneycontrol
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT - GlobeNewswire Inc.
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Dr Reddys Laboratories Faces Continued Stock Decline Amid Broader Market Challenges - Markets Mojo
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
NVO Stock Quote Price and Forecast - CNN
Asian Stocks Listed In The US Kicked Off The Week Lower - Finimize
Asian Stocks Dipped As US-Listed ADRs Edged Lower - Finimize
From Infosys, IndusInd Bank to Natco Pharma, 9 stocks to watch today - financialexpress.com
Stock Picks Today: Infosys, Dr. Reddys Labs, Kajaria Ceramics, Tata Consumer Products On Brokerages Radar - NDTV Profit
Asian Stocks Mixed As S&P Asia 50 ADR Index Falls - Finimize
Dr Reddy's Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - MSN
Dr. Reddy’s Labs ADR earnings missed, revenue fell short of estimates - Investing.com Australia
India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms - sg.finance.yahoo.com
Q1 Results Highlights: Infosys net profit rises 9%, Tata Consumer revenue jumps 10% - Moneycontrol
Dr Reddys Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - NDTV Profit
Dr. Reddy’s Laboratories Opens Special Window for Share Transfer Requests - TipRanks
Dr Reddys Laboratories Ltd Adr (RDY) 財務データ
収益
当期純利益
現金流量
EPS
2.06%
0.04%
大文字化:
|
ボリューム (24 時間):